Clinical Trial Results:
Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy.
Summary
|
|
EudraCT number |
2011-001191-19 |
Trial protocol |
DK |
Global end of trial date |
15 Apr 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Jul 2021
|
First version publication date |
02 Jul 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
2011-400
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01447654 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Rigshospitalet
|
||
Sponsor organisation address |
Blegdamsvej 9, København Ø, Denmark, 2100
|
||
Public contact |
Henning Bundgaard, Hjertemedicinsk klinik B, 2142, Rigshospitalet, +45 35450512, henningbundgaard@dadlnet.dk
|
||
Scientific contact |
Henning Bundgaard, Hjertemedicinsk klinik B, 2142, Rigshospitalet, +45 35450512, henningbundgaard@dadlnet.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
29 Jun 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
15 Apr 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Apr 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess whether treatment with losartan reduces left ventricular mass in patients with hypertrophic cardiomyopathy.
|
||
Protection of trial subjects |
None.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Nov 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 133
|
||
Worldwide total number of subjects |
133
|
||
EEA total number of subjects |
133
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
110
|
||
From 65 to 84 years |
23
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
Recruitment period: Dec 1, 2011, and May 1, 2013. | |||||||||
Pre-assignment
|
||||||||||
Screening details |
318 patients were screened. | |||||||||
Period 1
|
||||||||||
Period 1 title |
Treatment period (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Double blind | |||||||||
Roles blinded |
Subject, Investigator | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
Placebo | |||||||||
Arm description |
- | |||||||||
Arm type |
Placebo | |||||||||
Investigational medicinal product name |
Placebo
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
100 mg per day
|
|||||||||
Arm title
|
Losartan | |||||||||
Arm description |
- | |||||||||
Arm type |
Active comparator | |||||||||
Investigational medicinal product name |
Losartan
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
100 mg per day
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
- | ||
Reporting group title |
Losartan
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Left ventricular mass | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
12 months
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Primary endpoint | ||||||||||||
Comparison groups |
Placebo v Losartan
|
||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
- | ||||||||||||
upper limit |
- |
|
|||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
12 months
|
||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||
Dictionary name |
SUSAR | ||||||||||||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
Adverse event
|
||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
29 Jan 2012 |
Change in randomization process.
Change in acceptables leves of Creatinin and lever enzymes |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |